

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 13, 2023**

Streamline Health Solutions, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

0-28132
(Commission
File Number)

31-1455414
(I.R.S. Employer
Identification No.)

**2400 Old Milton Pkwy., Box 1353
Alpharetta, GA 30009**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(888) 997-8732**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, \$0.01 par value	STRM	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.05 Costs Associated with Exit Disposal Activities.

On October 16, 2023, Streamline Health Solutions, Inc. (the “Company”) announced a strategic restructuring designed to reduce expenses and preserve cash while maintaining the Company’s ability to expand its high-margin SaaS business. The strategic restructuring initiatives include a reduction in force that is expected to result in the termination of approximately 26 employees, representing approximately 24% of the Company’s workforce. The Company expects this workforce reduction to result in annual cost savings of approximately \$5.8 million.

The Company estimates the one-time restructuring costs associated with the workforce reduction to be approximately \$0.8 to \$1.2 million, which consists primarily of severance payments and related benefits to affected employees. The Company communicated the workforce reduction on October 13, 2023, and the Company expects the expense associated with the strategic restructuring to be substantially recognized by the end of fiscal 2023. The estimates of the costs and expenses the Company expects to incur in connection with the strategic restructuring, including the workforce reduction, are subject to a number of assumptions and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the strategic restructuring or workforce reduction.

A copy of the Company’s press release, dated October 16, 2023, announcing the strategic restructuring and workforce reduction is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Executive Chairman and Chief Executive Officer Transition

In connection with the strategic restructuring, the Company appointed Benjamin L. Stilwill as Chief Executive Officer of the Company, effective October 13, 2023. Mr. Stilwill is succeeding Wyche T. “Tee” Green, III as Chief Executive Officer, with Mr. Green transitioning to the role of Executive Chairman. Mr. Stilwill, age 34, joined the Company in 2013 and has served as President of the Company since October 2022.

Following his transition to the role of Executive Chairman, Mr. Green has agreed to forego a salary and will continue to serve as a director and as Chairman of the board of directors of the Company.

Appointment of Interim Chief Financial Officer

On October 13, 2023, the Company appointed Bryant “B.J.” Reeves as Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective October 13, 2023. Mr. Reeves will serve in such capacity until the Company appoints a full-time replacement to fill such roles.

Mr. Reeves, age 47, has served as the Company’s Chief of Staff since December 2022. Mr. Reeves previously served in corporate accounting and financial reporting management roles with the Company, including as the Director of Financial Planning and Analysis from October 2021 to December 2022 and as Director of Revenue from July 2020 to October 2021. Prior to joining the Company, Mr. Reeves held various senior finance and accounting roles with Agilysys, Inc., a publicly traded hospitality software solution developer, from June 2013 to July 2020.

There are no family relationships between Mr. Reeves and any director, executive officer, or any person nominated or chosen by the Company to become a director or executive officer. Mr. Reeves is not a party to, and does not have any director or indirect material interest in, any current or proposed transaction requiring disclosure under Item 404(a) of Regulation S-K.

In connection with the strategic restructuring, Thomas J. Gibson will no longer serve as Chief Financial Officer of the Company, effective October 13, 2023. Mr. Gibson will remain with the Company through October 31, 2023 to support the transition, at which time he will be entitled to severance benefits as set forth in his existing employment agreement. In connection with his departure, Mr. Gibson and the Company entered into a General Release, dated October 13, 2023 (the “Release”), pursuant to which the Company agreed to accelerate the vesting of 110,000 outstanding and unvested shares of restricted common stock of the Company previously granted to Mr. Gibson, subject to Mr. Gibson’s non-revocation of the Release and continued compliance with the other terms and conditions set forth in his employment agreement.

The foregoing description of the Release does not purport to be complete and is qualified in its entirety by reference to the copy of the Release filed as Exhibit 10.1 to this Current Report on Form 8-K, which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

EXHIBIT NUMBER	DESCRIPTION
10.1	General Release, dated October 13, 2023, by and between the Company and Thomas J. Gibson.
99.1	Press release, dated October 16, 2023.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STREAMLINE HEALTH SOLUTIONS, INC.

Date: October 16, 2023

By: /s/ Wyche T. "Tee" Green, III

Wyche T. "Tee" Green, III
Executive Chairman

GENERAL RELEASE

This **GENERAL RELEASE** (the "General Release") is entered into by Thomas J. Gibson, an individual resident of the State of Georgia ("Executive") in connection with Executive's separation from service with Streamline Health Solutions, Inc., a Delaware corporation (the "Company"). The General Release shall be effective on the day after the revocation period described in Section 8 expires (the "Effective Date").

WHEREAS, Executive and the Company previously entered into that certain Employment Agreement, dated September 10, 2018 (the "Employment Agreement");

WHEREAS, the Employment Agreement and Executive's employment with the Company were terminated, effective October 31, 2023 (the "Separation Date");

WHEREAS, Section 11(d) of the Employment Agreement provides that Executive will be entitled to receive certain severance benefits (the "Severance"), subject to Executive's timely execution and non-revocation of a general release of claims acceptable to the Company and Executive's compliance with the other terms and conditions set forth in the Employment Agreement;

WHEREAS, pursuant to that certain (i) Restricted Stock Award Agreement for Employees and Independent Contractors, dated May 20, 2022 (the "May RSA Agreement"), by and between Executive and the Company and (ii) Restricted Stock Award Agreement for Employees and Independent Contractors, dated November 1, 2022 (the "November RSA Agreement") together with the May RSA Agreement, the "Restricted Stock Agreements"), the Company issued 140,000 shares of restricted common stock of the Company to Executive (the "Restricted Stock"), subject to a three-year vesting schedule;

WHEREAS, in connection with the termination of the Employment Agreement and Executive's employment with the Company, the Company desires to accelerate the vesting of 110,000 outstanding and unvested shares of Restricted Stock held by Executive as of the Separation Date (the "Shares"), which Shares shall be deemed vested subject to Executive's timely execution and non-revocation of this General Release and compliance with the other terms and conditions set forth in the Employment Agreement; and

WHEREAS, in consideration of the foregoing, Executive desires to execute and deliver this General Release on the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the premises, mutual promises, and agreements of Executive and the Company set forth in the Employment Agreement and other good and valuable consideration, the receipt and sufficiency of which Executive hereby acknowledges, Executive agrees to the following:

1. **Claims Released by Executive.** Executive hereby voluntarily and irrevocably waives, releases and forever discharges (and, if applicable, agrees to dismiss with prejudice and withdraw) the Company, its subsidiaries and affiliates and their respective employees, officers directors, stockholders, members, agents, contractors, attorneys, insurers, plan administrators, representatives, successors and assigns (collectively, the "Releasees") of and from any and all actions, causes of action, claims, charges, complaints, suits, demands, losses, liabilities, obligations, costs and expenses of any kind whatsoever (whether known or unknown at the time of execution), which Executive ever had, may have, or now has against Releasees, whether arising from or relating to (directly or indirectly) the Employment Agreement, Executive's employment with the Company, the termination of the Employment Agreement and Executive's employment

with the Company, or other events that have occurred as of the Effective Date of this General Release, including but not limited to:

- (a) any claims under the Employment Agreement;
- (b) claims for violations of Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act (“ADEA”), the Fair Labor Standards Act, the Civil Rights Act of 1991, the Americans with Disabilities Act, the Equal Pay Act, 42 U.S.C. § 1981, the Family and Medical Leave Act, the National Labor Relations Act, the Occupational Safety and Health Act, or the Employee Retirement Income Security Act;
- (c) claims for violations of any other federal, state, or local statute, regulation, ordinance or executive order;
- (d) claims for wrongful termination, lost or unpaid wages, compensation or benefits, defamation, intentional or negligent infliction of emotional distress, assault, battery, constructive discharge, negligent hiring, retention or supervision, fraud, misrepresentation, conversion, tortious interference, breach of contract or breach of fiduciary duty;
- (e) claims to vacation or paid time off or compensation under any bonus, outplacement, commission or any other similar plan sponsored by the Company or its predecessors, successors, parent companies, subsidiaries or affiliates; and
- (f) any other claims under federal, state or local law arising in tort or contract.

By referencing the laws above, the Company does not admit to coverage of the Releasees under any of the laws referenced in this Section 1. Moreover, this General Release shall not in any way be construed as an admission by the Company or the Releasees of any improper action or liability whatsoever with respect to the Executive.

- 2. **Settlement, Accord, Satisfaction and Covenant Not to Sue.** Executive hereby acknowledges and agrees this General Release constitutes a full settlement, accord and satisfaction of all claims covered by the provisions set forth in Section 1. Except as set forth in Section 3, Executive promises not to sue or file any complaint or claim against any of the Releasees in any court of law based on any actual or alleged right, claim, act, or omission arising or occurring prior to the Effective Date, whether known or unknown at the time of execution.
- 3. **Claims Not Released by Executive.** Notwithstanding the foregoing, Executive acknowledges and agrees that Executive is not releasing:
 - (a) any claims which may arise under the terms of this General Release;
 - (b) any right to challenge the validity of the release of claims under the ADEA;
 - (c) any claims to the Severance or a failure to allow continued vesting of the Shares;
 - (d) any claims which may arise out of events occurring after the Effective Date;
 - (e) any claims which cannot be released under applicable law;
 - (f) any claims Executive may have as a stockholder of the Company;

- (g) any rights to contribution, offset, subrogation, regress, or directors and officers insurance coverage in the event Executive is sued, subpoenaed, served with process, deposed, or otherwise subject to, a defendant in, or involved in litigation against the Company brought by any current or former employees, contractors, stockholders, investors, financiers, or other stakeholders of the Company;
 - (h) any claims to vested benefits that Executive is already entitled to receive under any employee retirement or group healthcare benefit plans sponsored by the Company or its predecessors, successors, parent companies, subsidiaries or affiliates; or
 - (i) any right Executive has to benefits under workers' compensation laws, unemployment compensation laws or the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").
4. **Government Investigations and Proceedings.** Nothing in this General Release shall be construed to prohibit Executive from filing a charge with, or participating in any investigation or proceeding conducted by, the Equal Employment Opportunity Commission ("EEOC") or a comparable state or local agency. However, Executive hereby waives any right to receive future monetary recovery directly from the Releasees, including payments by the Releasees that result from any complaints or charges filed by, or on behalf of, Executive with any governmental agency (including the EEOC). Executive understands this General Release does not impact Executive's ability to receive and retain an award from a government-administered whistleblower award program for providing information directly to a government agency. In addition, Executive hereby releases, waives and forever discharges Executive's right to any portion of any settlement, judgment, or other recovery as a relator under the *qui tam* provisions of the False Claims Act, 31 U.S.C. § 3730 or any comparable state law, in any lawsuit arising from, or in any way related to, any transactions or occurrences involving the Releasees (in whole or in part) prior to the Effective Date, including, but not limited to, any right to receive expenses, attorney's fees, or costs under 31 U.S.C. § 3730(d) or otherwise.
5. **Return of Property and Information.** Executive represents and warrants that Executive has returned to the Company all property and information of the Company within Executive's possession or control. Such property and information includes, but is not limited to, the original and any copy (regardless of the manner in which it is recorded) of all information provided by the Company to Executive or which Executive has developed or collected in the scope of Executive's employment with the Company, as well as all Company-issued equipment, supplies, accessories, vehicles, keys, instruments, tools, devices, cell phones, pagers, materials, documents, plans, records, notebooks, drawings, or papers (collectively, "**Company Materials**"). Upon request by the Company, Executive shall certify in writing that Executive has complied with this **Section 5** and has returned all Company Materials and permanently deleted all the Company information from any computers or other electronic storage devices or media owned by Executive.
6. **Non-Disparagement.** Executive agrees that Executive will not at any time make, publish, or communicate to any person or entity or in any public forum any defamatory or disparaging remarks, comments, or statements concerning Releasees, including any such statements regarding Releasees' business, products or services or make any maliciously false statements about Releasees' employees or officers. Notwithstanding the foregoing, nothing in this General Release is intended to or will be used in any way to prevent Executive from testifying truthfully under oath

in a judicial proceeding or to limit Executive's right to communicate with a government agency, as provided for, protected under or warranted by applicable law.

7. **Cooperation.** Executive agrees that Executive shall, to the extent reasonably requested in writing, cooperate with the Company in any pending or future litigation or government investigation or proceeding in which the Company is a party, and regarding which Executive, by virtue of Executive's employment, has factual knowledge or information relevant to said litigation, investigation, or proceeding. Executive further agrees that in any such litigation, Executive shall, without the necessity for subpoena, provide, in any jurisdiction in which the Company requests, truthful testimony relevant to said litigation, investigation or proceeding. The Company will reimburse Executive for any reasonable, out-of-pocket expenses associated with providing such cooperation upon presentation of supporting documentation, no later than thirty (30) days after Executive incurs such expenses.
8. **Consideration Period and Option to Revoke.** Executive acknowledges and agrees that Executive has been given at least forty-five (45) calendar days to consider the terms of this General Release. Executive agrees that any changes made to this General Release after it was originally provided to Executive were not material and do not re-start the 45-day clock. Executive understands that Executive may revoke this General Release within seven (7) calendar days after execution thereof. If Executive revokes this General Release within the seven-day time period, this General Release will not become effective, and Executive will not receive the Severance and the Shares will not vest. Executive understands that upon the expiration of this seven-day revocation period, this General Release will be binding and irrevocable.
9. **Successors and Assigns.** This General Release will be binding upon Executive and Executive's heirs, administrators, representatives, executors, and successors. Executive agrees that the Company, without obtaining Executive's consent, may assign its rights and obligations hereunder to a wholly-owned subsidiary and provided further that any post-employment restrictions shall be assignable by the Company to any entity that purchases all or substantially all of the Company's assets. This General Release may not be assigned by Executive.
10. **Applicable Law.** This General Release shall be construed and interpreted in accordance with the laws of the State of Georgia (without giving effect to principles of conflicts of laws) to the extent such laws are not otherwise superseded by the laws of the United States. Executive agrees that any appropriate state or federal court located in the State of Georgia shall have exclusive jurisdiction of any case or controversy arising under or in connection with this General Release and shall be a proper forum in which to adjudicate such case or controversy. Executive consents to and waives any objection to the jurisdiction or venue of such courts.
11. **Understanding and Voluntary Execution.** Executive represents and warrants that:
 - (a) Executive has carefully read and fully understands all of the provisions of this General Release;
 - (b) Executive has been advised and directed to consult with an attorney of Executive's choice as to the terms of this General Release before signing the General Release;
 - (c) In signing this General Release, Executive does not rely on nor has Executive relied on any representation or statement, written or oral, not specifically set forth in this General Release, the Employment Agreement or the Restricted Stock Award Agreements by the

Company or by any of the Company's agents, representatives, or attorneys with regard to the subject matter, basis, or effect of this General Release or otherwise; and

- (d) Executive knowingly and voluntarily agrees to all the terms set forth in this General Release and intends to be legally bound by same.

IN WITNESS WHEREOF, Executive has signed and executed this General Release on the date set forth below as an expression of Executive's intent to be bound by the conditions and terms set forth herein.

DocuSigned by:

13577DC9A7E410...
Thomas J. Gibson

Date: 10/13/2023

Streamline Health[®] Executes Strategic Restructuring, Provides Corporate Update

- Executing strategic restructuring to reduce operating expenses and drive profitable growth of SaaS business; estimated annualized cost savings of approximately \$5.8 million
- Received termination notice from legacy client with a \$4.5M annualized revenue run rate
- Benjamin Stilwill appointed Chief Executive Officer
- Tee Green transitioning to Executive Chairman
- Bryant “B.J.” Reeves appointed interim Chief Financial Officer
- Company to host conference call at 9:00AM Eastern Time on October 16, 2023

Atlanta, GA – October 16, 2023 – Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced today it is executing a strategic restructuring. The strategic restructuring initiatives are designed to reduce expenses and preserve cash while maintaining the Company’s ability to expand its high-margin SaaS business.

As part of the strategic restructuring initiatives, the Company has implemented a reduction in force of approximately 26 employees (approximately 24% of its workforce). Streamline expects to record a one-time restructuring expense of approximately \$0.8 to \$1.2 million related to the reduction in force, which includes severance payments and benefits to affected employees. The Company expects the expense associated with the strategic restructuring to be substantially recognized by the end of fiscal 2023. As a result of these strategic restructuring initiatives, the Company expects to realize annualized cost savings of approximately \$5.8 million.

The Company also announced the receipt of a termination notice from a legacy client with an effective date of December 31, 2023. At the time of receipt of the termination notice, the Company was recognizing approximately \$4.5 million in annualized revenue from the legacy client. As a result of this termination notice, the Company’s management assessed various options and determined to accelerate the implementation of the Company’s planned restructuring initiatives.

The Company is suspending previous guidance related to Booked SaaS ACV and anticipates providing updates on future expectations in conjunction with the release of its fiscal third quarter 2023 financial results.

Management Changes

The Company also announced certain management changes and transitions in connection with the strategic restructuring. Effective October 13, 2023, Benjamin Stilwill has been appointed to the position of Chief Executive Officer of the Company. Mr. Stilwill will succeed Wyche T. “Tee” Green, III as Chief Executive Officer of the Company, with Mr. Green transitioning to the role of Executive Chairman at that time. Following his transition to the role of Executive Chairman, Mr. Green has agreed to forego a salary and will continue to serve as a director and as Chairman of the board of directors of the Company.

Mr. Stilwill most recently served as Streamline’s President and, prior to that, as CEO of the Company’s eValuator business. Mr. Stilwill was instrumental in developing a world class client success organization within eValuator focused on maintaining key client relationships and establishing a portfolio of referenceable accounts. Mr. Stilwill joined Streamline in 2013 as a senior financial analyst and has held various senior roles across the organization. Prior to joining Streamline Health, Mr. Stilwill was a financial analyst in BMO Capital Markets’ M&A Practice. Mr. Stilwill holds an Executive MBA from Villanova University and a Bachelor of Arts degree in Economics from DePauw University.

The Company also announced the appointment of Bryant “B.J.” Reeves as the Company’s Interim Chief Financial Officer, effective October 13, 2023. Mr. Reeves will succeed Thomas J. Gibson as Interim Chief Financial Officer of the Company, and Mr. Gibson will remain available to the Company through October 31, 2023 to ensure an orderly transition.

Mr. Reeves is an experienced financial and accounting leader. Mr. Reeves joined Streamline Health in 2020 and has held various roles in finance and accounting and most recently served as the Company’s Chief of Staff. From 2013-2020, Mr. Reeves held various senior accounting and finance roles at Agilysys, Inc., an industry-leading hospitality software solution developer. His career also included accounting roles at McKesson Corporation from 2001-2013, and he began his career as an accountant at Lockwood Greene in 1997. Mr. Reeves holds an MBA from Clemson University and has been a registered Certified Public Accountant since 2008.

Management Commentary

“We executed these strategic actions to increase our operational efficiency and ultimately thrive as an organization,” stated Benjamin Stilwill, Chief Executive Officer. “We have seen a significant increase in attention from our channel partners, and strong engagement from our prospects indicating growing demand in the marketplace for our innovative revenue cycle solutions, which coupled with the development progress we have made over the past 12 months within RevID should result in a broader client base.”

“Over the past several years with Streamline, I have witnessed an incredible evolution within our technology and our team,” stated Tee Green, Executive Chairman. “Ben has my utmost confidence, and I believe with his leadership this talented team will successfully deliver tremendous impact to our nation’s health systems.”

Conference Call

The Company will conduct a conference call later this morning on Monday, October 16, 2023 at 9:00AM ET to provide a corporate update. Interested parties can access the call by dialing 877-407-8291, or by joining the live webcast: [click here to register](#).

A replay of the conference call will be available from Monday, October 16, 2023 at 12:00PM ET through Monday, October 23, 2023 at 12:00PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13742119. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.

About Streamline Health

Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company's growth prospects, estimates of anticipated cash flow generation, expected costs of and cost savings related to workforce reductions and the anticipated period of time over which such expenses will be paid and cost savings will be realized, industry trends and market growth, results of investments in sales and marketing, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog and Booked SaaS ACV, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company's solutions, the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, the Company's ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Investors

Jacob Goldberger

Director, Investor Relations and FP&A

303.887.9625

jacob.goldberger@streamlinehealth.net
